Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning

Clinical trials for the CYD-TDV dengue vaccine showed that vaccine efficacy varies with prior dengue exposure, but baseline serostatus is only known for 12% of subjects. Here, Dorigatti et al. use machine learning to impute baseline serostatus and determine vaccine efficacy by baseline serostatus, a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: I. Dorigatti, C. A. Donnelly, D. J. Laydon, R. Small, N. Jackson, L. Coudeville, N. M. Ferguson
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Q
Acceso en línea:https://doaj.org/article/1e68c8a00b6d4e3c8a2064bb9e95ef0a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1e68c8a00b6d4e3c8a2064bb9e95ef0a
record_format dspace
spelling oai:doaj.org-article:1e68c8a00b6d4e3c8a2064bb9e95ef0a2021-12-02T15:34:23ZRefined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning10.1038/s41467-018-06006-62041-1723https://doaj.org/article/1e68c8a00b6d4e3c8a2064bb9e95ef0a2018-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-06006-6https://doaj.org/toc/2041-1723Clinical trials for the CYD-TDV dengue vaccine showed that vaccine efficacy varies with prior dengue exposure, but baseline serostatus is only known for 12% of subjects. Here, Dorigatti et al. use machine learning to impute baseline serostatus and determine vaccine efficacy by baseline serostatus, age and dengue serotype.I. DorigattiC. A. DonnellyD. J. LaydonR. SmallN. JacksonL. CoudevilleN. M. FergusonNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-9 (2018)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
I. Dorigatti
C. A. Donnelly
D. J. Laydon
R. Small
N. Jackson
L. Coudeville
N. M. Ferguson
Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
description Clinical trials for the CYD-TDV dengue vaccine showed that vaccine efficacy varies with prior dengue exposure, but baseline serostatus is only known for 12% of subjects. Here, Dorigatti et al. use machine learning to impute baseline serostatus and determine vaccine efficacy by baseline serostatus, age and dengue serotype.
format article
author I. Dorigatti
C. A. Donnelly
D. J. Laydon
R. Small
N. Jackson
L. Coudeville
N. M. Ferguson
author_facet I. Dorigatti
C. A. Donnelly
D. J. Laydon
R. Small
N. Jackson
L. Coudeville
N. M. Ferguson
author_sort I. Dorigatti
title Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
title_short Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
title_full Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
title_fullStr Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
title_full_unstemmed Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
title_sort refined efficacy estimates of the sanofi pasteur dengue vaccine cyd-tdv using machine learning
publisher Nature Portfolio
publishDate 2018
url https://doaj.org/article/1e68c8a00b6d4e3c8a2064bb9e95ef0a
work_keys_str_mv AT idorigatti refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning
AT cadonnelly refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning
AT djlaydon refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning
AT rsmall refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning
AT njackson refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning
AT lcoudeville refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning
AT nmferguson refinedefficacyestimatesofthesanofipasteurdenguevaccinecydtdvusingmachinelearning
_version_ 1718386826871308288